Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies

BACKGROUND: Two phase II studies in Japan examined the efficacy and safety of nivolumab, a programmed cell death 1 receptor inhibitor, in patients with advanced squamous and non-squamous non-small cell lung cancer (ONO-4538-05 and ONO-4538-06). We examined the long-term efficacy and safety of nivolu...

Descripción completa

Detalles Bibliográficos
Autores principales: Saka, Hideo, Nishio, Makoto, Hida, Toyoaki, Nakagawa, Kazuhiko, Sakai, Hiroshi, Nogami, Naoyuki, Atagi, Shinji, Takahashi, Toshiaki, Horinouchi, Hidehito, Takenoyama, Mitsuhiro, Katakami, Nobuyuki, Tanaka, Hiroshi, Takeda, Koji, Satouchi, Miyako, Isobe, Hiroshi, Maemondo, Makoto, Goto, Koichi, Hirashima, Tomonori, Minato, Koichi, Yada, Nobumichi, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767981/
https://www.ncbi.nlm.nih.gov/pubmed/33020837
http://dx.doi.org/10.1093/jjco/hyaa157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767981/
https://www.ncbi.nlm.nih.gov/pubmed/33020837
http://dx.doi.org/10.1093/jjco/hyaa157

Ejemplares similares